Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 6/20 | 0.53 |
| ▸ | CA1 | P00915 | 6/20 | 0.53 |
| ▸ | CA2 | P00918 | 6/20 | 0.53 |
| ▸ | CA9 | Q16790 | 6/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19434505 | 0.88 | TDP1 (0.46) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL17937439 | 0.88 | TDP1 (0.46) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL28800875 | 0.88 | TDP1 (0.58) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL30737456 | 0.87 | TDP1 (0.58) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL21068292 | 0.86 | CA12 (0.52) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL17286193 | 0.84 | CA12 (0.56) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL17941165 | 0.84 | CA12 (0.56) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL14524172 | 0.84 | TDP1 (0.71) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL22940247 | 0.84 | TDP1 (0.61) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL5576215 | 0.84 | TDP1 (0.71) | TDP1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | DRAUPNIR BIO APS (DK) | 2025-11-13 | — | — | US | disclosed |
| EP-4543858-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | Draupnir Bio ApS (DK) | 2025-04-30 | — | — | EP | disclosed |
| WO-2023247754-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | DRAUPNIR BIO APS (DK) | 2023-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | SORT1, SCARB1, LAMP1 | TDP1 2734/4885CA12 4066/4885CA1 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.